Ascendis Pharma A/S (ASND) Q4 2022 Results Conference Call February 16, 2023 4:30 PM ET

Company Participants

Tim Lee - Senior Director of Investor Relations

Jan Mikkelsen - President and Chief Executive Officer

Scott Smith - Executive Vice President, Chief Financial Officer

Stina Singel - Executive Vice President, Head of Clinical Development Oncology

Joe Kelly - Senior Vice President, Head of U.S. Commercial Endocrinology

Conference Call Participants

Jessica Fye - JPMorgan

Tazeen Ahmad - Bank of America

David Lebowitz - Citi

Li Watsek - Cantor

Paul Choi - Goldman

Derek Archila - Wells Fargo

Josh Schimmer - Evercore

Leland Gershell - Oppenheimer

Andreas Argyrides - Wedbush

Yaron Werber - Cowen

Operator

Good day, and thank you for standing by. Welcome to the Ascendis Pharma Full Year 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session [Operator Instructions]. Please be advised that, today's conference is being recorded.

I would now like to turn the call over to now your speaker for today, Tim Lee, Senior Director of Investor Relations. Please go ahead, the floor is yours.

Tim Lee

Thank you, operator, and thank you everyone for joining our full year 2022 financial results conference call. I'm Tim Lee, Senior Director of Investor Relations at Ascendis Pharma. Joining me on the call today is Jan Mikkelsen, President and Chief Executive Officer; Scott Smith, Executive Vice President and Chief Financial Officer; Dr. Stina Singel, Executive Vice President, Head of Clinical Development Oncology; and Joe Kelly, Senior Vice President, Head of U.S. Commercial Endocrinology. Before we begin, I would like to remind you that this conference call will contain forward-looking statements that are intended to be covered under the safe harbor provided by the Private Securities Litigation Reform Act. Examples of such statements may include, but are not limited to, our US commercialization and continued development of SKYTROFA for the US market, the commercialization of TransCon hGH for the EU market, statements regarding the expected timing of approval and launch of TransCon PTH in the US market next year, statements regarding expected timing of approval of TransCon PTH in Europe, statements regarding the potential the market size of TransCon PTH, our progress and our pipeline candidates and our expectations with respect to their continued progress, statements regarding our strategic plans, our goals regarding our clinical pipeline, including the timing of clinical results, statements regarding our pipeline product candidates, statements regarding planned regulatory filings, our expansion into new therapeutic areas and statements regarding the ability to create a sustainable leading global biopharma company.